SAPPHIRE Survey - DAY - Diabetes Awareness & You

We value your opinion. Kindly go through few important questions and share your views on it.

Name

Email ID

Mobile No

City

State

Pin Code

PAN

The above information is correct to best of knowledge & I do hereby give my consent to use the information of this survey for research work in future.

1. When do you initiate Dapagliflozin in the Management of T2DM in your clinical practice?

a. Newly diagnosed T2DM as Monotherapy

b. Failure to metformin monotherapy cases

c. As FDC with Metformin

d. After failure of metformin & other therapy options

2. What percentage of patients do you prescribe Dapagliflozin in your practice?

a) <10%

b) 10%-30%

c) 30%-50%

d) >50%

3. In your clinical opinion, how often do you check HbA1c?

a. Every 3 months

b. Every 4 months

c. Every 6 months

d. Yearly

4. How much HbA1C do you target for in your clinical practice?

a. <6.5 %

b. < 7 %

c. < 8 %

d. < 9 %

5. In your clinical practice what is the primary reason for T2DM patients coming for consultation?

a. Glycemic Control

b. Prevention of CV outcomes

c. Prevention of Renal Outcomes

d. All of the above

6. In your clinical practice, on an average how much HbA1C reduction do you notice with Dapagliflozin?

a. ≤ 0.5%

b. 0.5 - ≤1 %

c. > 1-≤ 2 %

d. > 2%

7. In your opinion, to have most of the benefits of Dapagliflozin when should it be ideally started in Management of T2DM?

a. Newly diagnosed T2DM as Monotherapy

b. Failure to metformin monotherapy cases

c. As FDC with Metformin

d. As 3rd line option after Metformin & other conventional OADs

8. What type of patients benefits more from Dapagliflozin in your clinical practice?

a. Heart Failure Patients

b. CKD Patients

c. Newly Diagnosed Type 2 Diabetes Patients

d. Poorly controlled Type 2 Diabetes Patients

e. All of the above

9. As per your clinical experience, Dapagliflozin is superior compared to other SGLT2 inhibitors in which clinical parameters?

a) Better glycemic durability

b) Reduction of CV events in HFrEF

c) Lesser renal adverse outcome

d) Extra-glycemic benefits

e) All of the above

10. In your clinical practice, what percentage of patients develops UTI after starting SGLT2inhibitors?

a. 1 –2 %

b. 5– 10 %

c. 10–15 %

d. 15 – 20 %